Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

AKT inhibition modulates H3K4 demethylase levels in PTEN null prostate cancer.

Khan MI, Hamid A, Rath S, Ateeq B, Khan Q, Siddiqui IA, Adhami VM, Choudhry H, Zamzami MA, Mukhtar H.

Mol Cancer Ther. 2018 Nov 16. pii: molcanther.0141.2018. doi: 10.1158/1535-7163.MCT-18-0141. [Epub ahead of print]

PMID:
30446585
2.

Pro-proliferative function of adaptor protein GRB10 in prostate carcinoma.

Khan MI, Al Johani A, Hamid A, Ateeq B, Manzar N, Adhami VM, Lall RK, Rath S, Sechi M, Siddiqui IA, Choudhry H, Zamzami MA, Havighurst TC, Huang W, Ntambi JM, Mukhtar H.

FASEB J. 2018 Oct 31:fj201800265RR. doi: 10.1096/fj.201800265RR. [Epub ahead of print]

PMID:
30379590
3.

Chitosan-based nanoformulated (-)-epigallocatechin-3-gallate (EGCG) modulates human keratinocyte-induced responses and alleviates imiquimod-induced murine psoriasiform dermatitis.

Chamcheu JC, Siddiqui IA, Adhami VM, Esnault S, Bharali DJ, Babatunde AS, Adame S, Massey RJ, Wood GS, Longley BJ, Mousa SA, Mukhtar H.

Int J Nanomedicine. 2018 Jul 20;13:4189-4206. doi: 10.2147/IJN.S165966. eCollection 2018.

4.

Nummularic acid, a triterpenoid, from the medicinal plant Fraxinus xanthoxyloides, induces energy crisis to suppress growth of prostate cancer cells.

Younis T, Khan MI, Khan MR, Rasul A, Majid M, Adhami VM, Mukhtar H.

Mol Carcinog. 2018 Oct;57(10):1267-1277. doi: 10.1002/mc.22841. Epub 2018 Jun 5.

PMID:
29802724
5.

Targeting epigenome with dietary nutrients in cancer: Current advances and future challenges.

Khan MI, Rath S, Adhami VM, Mukhtar H.

Pharmacol Res. 2018 Mar;129:375-387. doi: 10.1016/j.phrs.2017.12.008. Epub 2017 Dec 9. Review.

PMID:
29233676
6.

Hypoxia driven glycation: Mechanisms and therapeutic opportunities.

Khan MI, Rath S, Adhami VM, Mukhtar H.

Semin Cancer Biol. 2018 Apr;49:75-82. doi: 10.1016/j.semcancer.2017.05.008. Epub 2017 May 22. Review.

PMID:
28546110
7.

Targeted nanoparticles encapsulating (-)-epigallocatechin-3-gallate for prostate cancer prevention and therapy.

Sanna V, Singh CK, Jashari R, Adhami VM, Chamcheu JC, Rady I, Sechi M, Mukhtar H, Siddiqui IA.

Sci Rep. 2017 Feb 1;7:41573. doi: 10.1038/srep41573.

8.

Fisetin Enhances Chemotherapeutic Effect of Cabazitaxel against Human Prostate Cancer Cells.

Mukhtar E, Adhami VM, Siddiqui IA, Verma AK, Mukhtar H.

Mol Cancer Ther. 2016 Dec;15(12):2863-2874. Epub 2016 Oct 7.

9.

Dual Inhibition of PI3K/Akt and mTOR by the Dietary Antioxidant, Delphinidin, Ameliorates Psoriatic Features In Vitro and in an Imiquimod-Induced Psoriasis-Like Disease in Mice.

Chamcheu JC, Adhami VM, Esnault S, Sechi M, Siddiqui IA, Satyshur KA, Syed DN, Dodwad SM, Chaves-Rodriquez MI, Longley BJ, Wood GS, Mukhtar H.

Antioxid Redox Signal. 2017 Jan 10;26(2):49-69. doi: 10.1089/ars.2016.6769. Epub 2016 Oct 4.

10.

Dietary flavonoid fisetin increases abundance of high-molecular-mass hyaluronan conferring resistance to prostate oncogenesis.

Lall RK, Syed DN, Khan MI, Adhami VM, Gong Y, Lucey JA, Mukhtar H.

Carcinogenesis. 2016 Sep;37(9):918-928. doi: 10.1093/carcin/bgw071. Epub 2016 Jun 22.

11.

Nutrition in the cause and prevention of cancer: An update.

Adhami VM, Mukhtar H.

Mol Nutr Food Res. 2016 Jun;60(6):1226-7. doi: 10.1002/mnfr.201670064. No abstract available.

PMID:
27276214
12.

Exploring the molecular targets of dietary flavonoid fisetin in cancer.

Syed DN, Adhami VM, Khan N, Khan MI, Mukhtar H.

Semin Cancer Biol. 2016 Oct;40-41:130-140. doi: 10.1016/j.semcancer.2016.04.003. Epub 2016 May 6. Review.

13.

Dietary flavonoid fisetin for cancer prevention and treatment.

Lall RK, Adhami VM, Mukhtar H.

Mol Nutr Food Res. 2016 Jun;60(6):1396-405. doi: 10.1002/mnfr.201600025. Epub 2016 May 6. Review.

14.

Upregulation of PI3K/AKT/mTOR, FABP5 and PPARβ/δ in Human Psoriasis and Imiquimod-induced Murine Psoriasiform Dermatitis Model.

Chamcheu JC, Chaves-Rodriquez MI, Adhami VM, Siddiqui IA, Wood GS, Longley BJ, Mukhtar H.

Acta Derm Venereol. 2016 Aug 23;96(6):854-6. doi: 10.2340/00015555-2359. No abstract available.

15.

The pentacyclic triterpenoid, plectranthoic acid, a novel activator of AMPK induces apoptotic death in prostate cancer cells.

Akhtar N, Syed DN, Khan MI, Adhami VM, Mirza B, Mukhtar H.

Oncotarget. 2016 Jan 26;7(4):3819-31. doi: 10.18632/oncotarget.6625.

16.

Dietary flavonoid fisetin binds to β-tubulin and disrupts microtubule dynamics in prostate cancer cells.

Mukhtar E, Adhami VM, Sechi M, Mukhtar H.

Cancer Lett. 2015 Oct 28;367(2):173-83. doi: 10.1016/j.canlet.2015.07.030. Epub 2015 Jul 30.

17.

Dietary polyphenols in prevention and treatment of prostate cancer.

Lall RK, Syed DN, Adhami VM, Khan MI, Mukhtar H.

Int J Mol Sci. 2015 Feb 3;16(2):3350-76. doi: 10.3390/ijms16023350. Review.

18.

Prodifferentiation, anti-inflammatory and antiproliferative effects of delphinidin, a dietary anthocyanidin, in a full-thickness three-dimensional reconstituted human skin model of psoriasis.

Chamcheu JC, Pal HC, Siddiqui IA, Adhami VM, Ayehunie S, Boylan BT, Noubissi FK, Khan N, Syed DN, Elmets CA, Wood GS, Afaq F, Mukhtar H.

Skin Pharmacol Physiol. 2015;28(4):177-88. doi: 10.1159/000368445. Epub 2015 Jan 22.

19.

Topical application of delphinidin reduces psoriasiform lesions in the flaky skin mouse model by inducing epidermal differentiation and inhibiting inflammation.

Pal HC, Chamcheu JC, Adhami VM, Wood GS, Elmets CA, Mukhtar H, Afaq F.

Br J Dermatol. 2015 Feb;172(2):354-64. doi: 10.1111/bjd.13513. Epub 2014 Dec 23.

20.

Role of epithelial mesenchymal transition in prostate tumorigenesis.

Khan MI, Hamid A, Adhami VM, Lall RK, Mukhtar H.

Curr Pharm Des. 2015;21(10):1240-8. Review.

21.

Cancer chemoprevention is not a failure.

Adhami VM, Bailey HH, Mukhtar H.

Carcinogenesis. 2014 Sep;35(9):2154-5. doi: 10.1093/carcin/bgu141. Epub 2014 Jun 26. No abstract available.

PMID:
24970761
22.

Excellent anti-proliferative and pro-apoptotic effects of (-)-epigallocatechin-3-gallate encapsulated in chitosan nanoparticles on human melanoma cell growth both in vitro and in vivo.

Siddiqui IA, Bharali DJ, Nihal M, Adhami VM, Khan N, Chamcheu JC, Khan MI, Shabana S, Mousa SA, Mukhtar H.

Nanomedicine. 2014 Nov;10(8):1619-26. doi: 10.1016/j.nano.2014.05.007. Epub 2014 Jun 3.

PMID:
24965756
23.

YB-1 expression promotes epithelial-to-mesenchymal transition in prostate cancer that is inhibited by a small molecule fisetin.

Khan MI, Adhami VM, Lall RK, Sechi M, Joshi DC, Haidar OM, Syed DN, Siddiqui IA, Chiu SY, Mukhtar H.

Oncotarget. 2014 May 15;5(9):2462-74.

24.

Fisetin inhibits human melanoma cell growth through direct binding to p70S6K and mTOR: findings from 3-D melanoma skin equivalents and computational modeling.

Syed DN, Chamcheu JC, Khan MI, Sechi M, Lall RK, Adhami VM, Mukhtar H.

Biochem Pharmacol. 2014 Jun 1;89(3):349-60. doi: 10.1016/j.bcp.2014.03.007. Epub 2014 Mar 24.

25.

Targeting microtubules by natural agents for cancer therapy.

Mukhtar E, Adhami VM, Mukhtar H.

Mol Cancer Ther. 2014 Feb;13(2):275-84. doi: 10.1158/1535-7163.MCT-13-0791. Epub 2014 Jan 16. Review.

26.

Oral administration of naturally occurring chitosan-based nanoformulated green tea polyphenol EGCG effectively inhibits prostate cancer cell growth in a xenograft model.

Khan N, Bharali DJ, Adhami VM, Siddiqui IA, Cui H, Shabana SM, Mousa SA, Mukhtar H.

Carcinogenesis. 2014 Feb;35(2):415-23. doi: 10.1093/carcin/bgt321. Epub 2013 Sep 26.

27.

The S100A4 Oncoprotein Promotes Prostate Tumorigenesis in a Transgenic Mouse Model: Regulating NFκB through the RAGE Receptor.

Siddique HR, Adhami VM, Parray A, Johnson JJ, Siddiqui IA, Shekhani MT, Murtaza I, Ambartsumian N, Konety BR, Mukhtar H, Saleem M.

Genes Cancer. 2013 May;4(5-6):224-34. doi: 10.1177/1947601913492420.

28.

The dietary terpene lupeol targets colorectal cancer cells with constitutively active Wnt/β-catenin signaling.

Tarapore RS, Siddiqui IA, Adhami VM, Spiegelman VS, Mukhtar H.

Mol Nutr Food Res. 2013 Nov;57(11):1950-8. doi: 10.1002/mnfr.201300155. Epub 2013 Jul 9.

29.

Delphinidin, a dietary antioxidant, induces human epidermal keratinocyte differentiation but not apoptosis: studies in submerged and three-dimensional epidermal equivalent models.

Chamcheu JC, Afaq F, Syed DN, Siddiqui IA, Adhami VM, Khan N, Singh S, Boylan BT, Wood GS, Mukhtar H.

Exp Dermatol. 2013 May;22(5):342-8. doi: 10.1111/exd.12140.

30.

Inhibition of Akt/mTOR signaling by the dietary flavonoid fisetin.

Syed DN, Adhami VM, Khan MI, Mukhtar H.

Anticancer Agents Med Chem. 2013 Sep;13(7):995-1001. Review.

31.

Apoptosis and autophagy induction as mechanism of cancer prevention by naturally occurring dietary agents.

Mukhtar E, Adhami VM, Khan N, Mukhtar H.

Curr Drug Targets. 2012 Dec;13(14):1831-41. Review.

32.

Pomegranate extracts and cancer prevention: molecular and cellular activities.

Syed DN, Chamcheu JC, Adhami VM, Mukhtar H.

Anticancer Agents Med Chem. 2013 Oct;13(8):1149-61. Review.

33.

Dietary flavonoid fisetin: a novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management.

Adhami VM, Syed DN, Khan N, Mukhtar H.

Biochem Pharmacol. 2012 Nov 15;84(10):1277-81. doi: 10.1016/j.bcp.2012.07.012. Epub 2012 Jul 25. Review.

34.

Human cancer chemoprevention: hurdles and challenges.

Adhami VM, Mukhtar H.

Top Curr Chem. 2013;329:203-20. doi: 10.1007/128_2012_342. Review.

PMID:
22790416
35.

Progress towards genetic and pharmacological therapies for keratin genodermatoses: current perspective and future promise.

Chamcheu JC, Wood GS, Siddiqui IA, Syed DN, Adhami VM, Teng JM, Mukhtar H.

Exp Dermatol. 2012 Jul;21(7):481-9. doi: 10.1111/j.1600-0625.2012.01534.x. Review.

36.

Impact of nanotechnology in cancer: emphasis on nanochemoprevention.

Siddiqui IA, Adhami VM, Chamcheu JC, Mukhtar H.

Int J Nanomedicine. 2012;7:591-605. doi: 10.2147/IJN.S26026. Epub 2012 Feb 2. Review.

37.

Oral infusion of pomegranate fruit extract inhibits prostate carcinogenesis in the TRAMP model.

Adhami VM, Siddiqui IA, Syed DN, Lall RK, Mukhtar H.

Carcinogenesis. 2012 Mar;33(3):644-51. doi: 10.1093/carcin/bgr308. Epub 2011 Dec 22.

38.

α-Mangostin, a xanthone from mangosteen fruit, promotes cell cycle arrest in prostate cancer and decreases xenograft tumor growth.

Johnson JJ, Petiwala SM, Syed DN, Rasmussen JT, Adhami VM, Siddiqui IA, Kohl AM, Mukhtar H.

Carcinogenesis. 2012 Feb;33(2):413-9. doi: 10.1093/carcin/bgr291. Epub 2011 Dec 9.

39.

Butein induces apoptosis and inhibits prostate tumor growth in vitro and in vivo.

Khan N, Adhami VM, Afaq F, Mukhtar H.

Antioxid Redox Signal. 2012 Jun 1;16(11):1195-204. doi: 10.1089/ars.2011.4162. Epub 2012 Jan 16.

40.

Nanoparticle delivery of natural products in the prevention and treatment of cancers: current status and future prospects.

Bharali DJ, Siddiqui IA, Adhami VM, Chamcheu JC, Aldahmash AM, Mukhtar H, Mousa SA.

Cancers (Basel). 2011 Oct 26;3(4):4024-45. doi: 10.3390/cancers3044024.

41.

Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer.

Siddiqui IA, Asim M, Hafeez BB, Adhami VM, Tarapore RS, Mukhtar H.

FASEB J. 2011 Apr;25(4):1198-207. doi: 10.1096/fj.10-167924. Epub 2010 Dec 21.

42.

Keratin gene mutations in disorders of human skin and its appendages.

Chamcheu JC, Siddiqui IA, Syed DN, Adhami VM, Liovic M, Mukhtar H.

Arch Biochem Biophys. 2011 Apr 15;508(2):123-37. doi: 10.1016/j.abb.2010.12.019. Epub 2010 Dec 19. Review.

43.

Nanochemoprevention: sustained release of bioactive food components for cancer prevention.

Siddiqui IA, Adhami VM, Ahmad N, Mukhtar H.

Nutr Cancer. 2010;62(7):883-90. doi: 10.1080/01635581.2010.509537. Review.

44.

Specific targeting of Wnt/β-catenin signaling in human melanoma cells by a dietary triterpene lupeol.

Tarapore RS, Siddiqui IA, Saleem M, Adhami VM, Spiegelman VS, Mukhtar H.

Carcinogenesis. 2010 Oct;31(10):1844-53. doi: 10.1093/carcin/bgq169. Epub 2010 Aug 23.

45.

Review: green tea polyphenols in chemoprevention of prostate cancer: preclinical and clinical studies.

Khan N, Adhami VM, Mukhtar H.

Nutr Cancer. 2009;61(6):836-41. doi: 10.1080/01635580903285056. Review.

46.

Cancer chemoprevention by pomegranate: laboratory and clinical evidence.

Adhami VM, Khan N, Mukhtar H.

Nutr Cancer. 2009;61(6):811-5. doi: 10.1080/01635580903285064. Review.

47.

Dietary zinc and prostate cancer in the TRAMP mouse model.

Prasad AS, Mukhtar H, Beck FW, Adhami VM, Siddiqui IA, Din M, Hafeez BB, Kucuk O.

J Med Food. 2010 Feb;13(1):70-6. doi: 10.1089/jmf.2009.0042.

48.

Apoptosis by dietary agents for prevention and treatment of prostate cancer.

Khan N, Adhami VM, Mukhtar H.

Endocr Relat Cancer. 2010 Jan 29;17(1):R39-52. doi: 10.1677/ERC-09-0262. Print 2010 Mar. Review.

49.

Fisetin, a natural flavonoid, targets chemoresistant human pancreatic cancer AsPC-1 cells through DR3-mediated inhibition of NF-kappaB.

Murtaza I, Adhami VM, Hafeez BB, Saleem M, Mukhtar H.

Int J Cancer. 2009 Nov 15;125(10):2465-73. doi: 10.1002/ijc.24628.

50.

Effective prostate cancer chemopreventive intervention with green tea polyphenols in the TRAMP model depends on the stage of the disease.

Adhami VM, Siddiqui IA, Sarfaraz S, Khwaja SI, Hafeez BB, Ahmad N, Mukhtar H.

Clin Cancer Res. 2009 Mar 15;15(6):1947-53. doi: 10.1158/1078-0432.CCR-08-2332. Epub 2009 Mar 10.

Supplemental Content

Loading ...
Support Center